To determine the effects of intra-articular administration of recombinant human fibroblast growth factor 18 (rhFGF18, AS902330) in a pilot study of a dog meniscectomy model for established osteoarthritis. Methods: A unilateral partial medial meniscectomy was performed on the left knee of female beagle dogs 1 month prior to intra-articular administration of 3, 10 or 30 mg/joint of AS902330 or saline (control) as a single dose, or as a once-weekly or 3-times-weekly (tiw; 3, 10 or 30 mg divided between 3 doses) dose for 3 weeks. At treatment end (day 22), the dogs were anaesthetized before euthanasia. Left knee joints were collected for gross, microscopic and histopathological evaluation. A scoring system was used for histopathology of the cartilage and for gross pathology; reading was conducted in a blinded manner. Blood and serum were collected prior to dosing, on days 7, 14, 18 and 21 and at time of death, and exposure was determined using high performance ELISA. Results: In total, 13 groups of 3 dogs each underwent surgery and, after 1 month of disease progression, were randomly assigned to a treatment, including an untreated control group. The dosing procedure was well tolerated by all dogs. Dogs treated once with 30 mg AS902330 had improved gross scores for the medial tibial plateau (40%) and tibial and femoral cartilage degeneration (40%), compared with controls. Decreased combined gross scores were evident for most AS902330-treated knees compared with controls. Microscopic evaluation revealed definite anabolic effects, including increased cloning, cellularity and proteoglycan staining in lesion areas in dogs treated with 30 mg AS902330; these changes were most identifiable on femoral condyles. Convincing anabolic effects were observed in a dose-dependent manner at the lower tiw and once-weekly doses. AS902330-induced effects were found in the upper third to half of the cartilage or matrix adjacent to deeper clefts. Dogs from all treatment groups showed a reduction in histopathological tibial cartilage degeneration; the greatest decrease was in dogs treated once weekly with 30 mg AS902330. Synovitis was minimal or mild with no difference between groups, and subchondral bone sclerosis was highly variable. No treatment-related changes in clinical chemistry parameters or haematology were noted. Additionally, no systemic effects were seen at any dose, as assessed using cartilage thickness in the ear, sternum and trachea. Systemic exposure after intra-articular administration of AS902330 was below the lower limit of quantification (50 pg/mL). Conclusions: Intra-articular treatment with the anabolic agent AS902330 30 mg/wk resulted in definite anabolic effects in all treated knees, with no apparent systemic effects. AS902330 demonstrated efficacy in the improvement of gross pathology and histopathology scoring in a dosedependent manner in this pilot study involving a dog meniscectomy model, supporting earlier findings in rats. 
Purpose:
We have developed a novel recombinant lubricin construct, LUB:1, which is chondroprotective and prevents cartilage degeneration in a rat meniscal tear model of osteoarthritis (OA). LUB:1 contains a truncated mucin-like domain, and maintains essential properties of cartilage binding and lubrication, and prevention of cell adhesion. The goal of this study was to determine the residence time and tissue localization of radiolabelled LUB:1 following intra-articular administration in the knee joints of rats. Methods: Male Lewis rats were dosed with a single bilateral intra-articular injection of 125 I-labeled LUB:1 (1 mCi; 20 mg/knee) and the knee joints were collected at different time points (0.2 hours-672 hours). The retention of 125 I-labeled LUB:1 and tissue localization in the knee were assessed by gamma counting of whole knees and dissected joint tissues (cartilage, synovium, meniscus) and autoradiography. Results: A fast decline in 125 I-LUB:1 concentrations in the whole knee occurred during the first 24 hours (initial phase), indicating rapid clearance from the synovial fluid (i.e. via lymphatic transport) as has been described for other macromolecules such as hyaluronan and albumin. This was followed by a slow decline in 125 I-LUB:1 levels, up to 672 hours. The average elimination half-life of intra-articularly injected LUB:1, determined from a one-compartmental fit, was 152 hours. 125 I-LUB:1 remained detectable in the knee joint (particularly on the articular cartilage and synovium) even at 672 hours (28 days) after a single injection. 125 I-LUB:1 localized onto the surfaces of articular cartilage (tibial plateau, femoral condyle and meniscus), synovium and cruciate ligament as determined by autoradiography. Conclusions: These data indicate that intra-articularly delivered LUB:1 localizes to the surfaces of joint tissues, including articular cartilage, suggesting that at least part of its mechanism of action for slowing OA progression may be by providing a protective coating at cartilage surfaces. The extended tissue residence time of LUB:1 in the joint supports strategies for potential application of recombinant lubricin molecules as therapeutics in the clinic.
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Purpose: In the field of osteoarthritis (OA) research, there is no consensus as to which animal model best represents human OA, particularly because the disease process isn't completely understood. The primary objective of this study was to validate the robustness of the ovarectomy (OVX) model as a model of OA. The study was also used to identify relevant therapeutic endpoints and to determine if rat strain plays a role in the severity of the disease state. Endpoints reported in the literature for this model were used as positive controls to monitor the progression of the model. Several additional novel endpoints were also tested. Methods: At 20 weeks (5 months) of age, 6 Sprague Dawley (SD) and 7 Long Evans (LE) female rats underwent OVX and 2 of each strain underwent sham OVX. Weekly urine samples were collected beginning at 6 weeks. These were analyzed using the RatLaps TM ELISA (CTX-I) and Urine Pre-Clinical CartiLaps ® ELISA (CTX-II) kits (Nordic Biosciences) to identify bone and cartilage breakdown products. The animals were euthanized at 10 and 14 weeks post OVX (3 OVX/1 sham per breed per time-point.) The right elbow and right stifle (knee) joint were harvested and snap frozen for RNA harvest and qPCR analysis. The genes analyzed by qPCR included extra cellular matrix molecules, cytokines, cytokine receptors, metalloproteases and growth factors. The left elbow and a control knee were harvested and placed into fixative for scanning electron microscopy (SEM) analysis. The left knee of each animal was fixed for mCT imaging of bone architecture and later histological processing (H&E, safranin-O and toluidine blue). A specially designed holder was used to maintain flexion and to allow for consistent imaging of the joint space with a faxitron. Measurements of the joint space were then made using Image-Pro ® Software. Results: The OVX model has been described in the literature as a model for both osteoporosis and osteoarthritis. Previous studies have reported significant changes in the breakdown of bone and cartilage in the ovariectomized animal. In keeping with these findings, the OVX groups of both strains displayed initially elevated urinary CTX-I and II. The qPCR gene analysis of the knees showed that certain extra-cellular matrix proteins and proteases also tended to be higher at week 10 than at week 14. In spite of these findings, SEM analysis did not show any articulating surface damage on the condyles of the distal femur, humerus or ulna articulating surfaces. No significant differences were seen in the joint narrowing index at weeks 10 and 14 between test and control animals. There were, however, significant bone changes following OVX, as measured by mCT in both strains of rats. The LE rats displayed more significant bone changes than the SD. The pathology results showed that no animals developed the classical morphological changes associated with OA. At 10 and 14 weeks post-OVX, there was complete tidemark integrity, normal cell organization and intact cartilage structure in the knees of all animals. Conclusions: More significant osteoarthritic changes were expected based upon previous findings. It may be that older animals or later time points would demonstrate greater degeneration of bone and cartilage or that exercise could be used to hasten these changes. Ovariectomy may be better utilized as a background for other models.
